Phase 1 dose escalation study of the MDM2 inhibitor milademetan as monotherapy and in combination with azacitidine in patients with myeloid malignancies

Abstract Background Mouse double minute‐2 homolog (MDM2) plays a key role in downregulating p53 activity in hematologic malignancies, and its overexpression is associated with poor outcomes. Methods This phase 1 study assessed the safety and efficacy of different dosing regimens of the MDM2 inhibito...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Courtney D. DiNardo, Rebecca Olin, Eunice S. Wang, Barry Skikne, Joseph Rosenthal, Prasanna Kumar, Hiroyuki Sumi, Yoshiyuki Hizukuri, Ying Hong, Parul Patel, Takahiko Seki, Tao Duan, Arnaud Lesegretain, Michael Andreeff
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	Wiley 2024-07-01
Schriftenreihe:	Cancer Medicine
Schlagworte:	acute myeloid leukemia milademetan mouse double minute‐2 homolog myelodysplastic syndromes
Online-Zugang:	https://doi.org/10.1002/cam4.70028
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!